The earnings call reflected a mix of positive developments such as strong demand for Rolvedon and successful legal settlements, but also faced challenges including a decline in net product sales and the discontinuation of Otrexup commercialization. The company's financial position remains strong, which supports future strategic transactions.

Company Guidance

During the Assertio Holdings Second Quarter 2025 Results Conference Call, guidance was provided that adjusted the company's outlook for the year. Assertio has slightly reduced the top end of its revenue range due to ceasing commercialization of Otrexup, but it has increased the lower end of its adjusted EBITDA outlook, emphasizing improved profitability. For the second quarter, net product sales were $28.8 million, with Rolvedon sales at $16.1 million, Sympazan at $3.2 million, and Indocin at $3 million. The company updated its annual guidance range for net product sales to $108 million to $118 million and adjusted EBITDA to a range of $11 million to $19 million. The call also highlighted successful strategic initiatives like reducing legal exposure, simplifying corporate structures, and prioritizing investments in growth assets to drive long-term value creation.

Strong Rolvedon Provider Demand

Rolvedon sales were $16.1 million, up from $15.1 million in the prior year quarter, driven by higher volume and favorability from returns reserve adjustment. Provider demand volume was the highest since launch, with a 20% increase from Q1 to Q2.

Sympazan Growth

Sympazan sales were $3.2 million, up from $2.7 million in the prior year period, reflecting higher volume and favorable payer mix. The company expects net sales to potentially double in the next several years.

Successful Legal Settlements

Assertio settled multiple legal matters, including the 2017 qui tam lawsuit and Glumetza antitrust action, reducing ongoing legal costs and business uncertainty.

Cash Position and Financial Flexibility

Cash, cash equivalents, and short-term investments totaled $98.2 million, an increase from $87.3 million as of March 31, 2025, driven by positive operating cash flows.

Assertio Therapeutics (ASRT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ASRT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.09 / -	-0.03	―	―	―
Aug 11, 2025	2025 (Q2)	-0.09 / -0.17	-0.04	-325.00% (-0.13)	―
May 12, 2025	2025 (Q1)	-0.06 / -0.14	-0.05	-180.00% (-0.09)	―
Mar 12, 2025	2024 (Q4)	-0.04 / -0.11	0.11	-200.00% (-0.22)	―
Nov 11, 2024	2024 (Q3)	-0.05 / -0.03	0.01	-400.00% (-0.04)	―
Aug 07, 2024	2024 (Q2)	-0.03 / -0.04	0.19	-121.05% (-0.23)	―
May 06, 2024	2024 (Q1)	-0.01 / -0.05	0.29	-117.24% (-0.34)	―
Mar 11, 2024	2023 (Q4)	0.00 / 0.11	0.32	-65.63% (-0.21)	―
Nov 08, 2023	2023 (Q3)	0.10 / 0.01	0.22	-95.45% (-0.21)	―
Aug 03, 2023	2023 (Q2)	0.19 / 0.19	0.28	-32.14% (-0.09)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ASRT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$0.72	$0.82	+13.89%
May 12, 2025	$0.62	$0.61	-1.61%
Mar 12, 2025	$0.78	$0.72	-7.69%
Nov 11, 2024	$0.92	$0.85	-7.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Assertio Therapeutics Inc (ASRT) report earnings?

Assertio Therapeutics Inc (ASRT) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Assertio Therapeutics Inc (ASRT) earnings time?

Assertio Therapeutics Inc (ASRT) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ASRT EPS forecast?

ASRT EPS forecast for the fiscal quarter 2025 (Q3) is -0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing